(Q40338516)

19 September 2017

Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency (English)

1 reference

19 September 2017

1 reference

Alaupovic P

1

1 reference

19 September 2017

Attman PO

2

1 reference

19 September 2017

Knight-Gibson C

3

1 reference

19 September 2017

Mulec H

4

1 reference

19 September 2017

Weiss L

5

1 reference

19 September 2017

Samuelsson O

6

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

19 September 2017

1 reference

19 September 2017

69

1 reference

19 September 2017

10

1 reference

19 September 2017

1865-1871

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000327

19 September 2017

0 references

cites work

Lipoprotein metabolism and renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

The concept of apolipoprotein-defined lipoprotein families and its clinical significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Apolipoprotein A-I containing lipoproteins in coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Separation and identification of apo-B-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Fluvastatin: clinical and safety profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Lipid-lowering therapy in patients with renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Disruption of endothelial barrier function by lipolytic remnants of triglyceride-rich lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Lipids and the endothelium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Evidence that triglycerides are an independent coronary heart disease risk factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Identification and partial characterization of discrete apolipoprotein B containing lipoprotein particles produced by human hepatoma cell line HepG2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Determination of Glomerular Filtration Rate in Advanced Renal Insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000327

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000327

1 reference

release_p35ivi4bwjbwdkf3lpfiwaupna

19 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p35ivi4bwjbwdkf3lpfiwaupna

24 November 2022

mapped directly with Wikidata item

1 reference